- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Contrast-Enhanced US Differentiates Between Malignant/Benign Renal Lesions
Largest study in Europe for the evaluation of renal lesions using CEUS with a histopathological validation.
Contrast-enhanced ultrasound (CEUS) helps differentiate between malignant and benignant renal lesions, according to a study published in the journal European Radiology.
Researchers from Germany sought to investigate the usefulness of CEUS in the evaluation of renal masses. A total of 225 patients with renal masses, ranging in age from 18 to 86 years, were included in the study. CEUS was used for determining malignancy or benignancy and findings were correlated with the histopathological outcome. Out of 255 lesions, 212 lesions (83.1%) were malignant and 43 (16.9%) were benign. Diagnostic accuracy was tested using the histopathological diagnosis as the gold standard.
Related article: Revitalizing Ultrasound
The results showed that CEUS had a sensitivity of 99.1%, a specificity of 80.5%, a positive predictive value of 96.4% and a negative predictive value of 94.3%. Kappa for diagnostic accuracy was κ = 0.85. Of 212 malignant lesions, 200 renal cell carcinomas and 12 other malignant lesions were diagnosed. Out of 43 benign lesions, 10 angiomyolipomas, 3 oncocytomas, 8 renal cysts and 22 other benign lesions were diagnosed.
The researchers concluded that CEUS is an useful method to differentiate between malignant and benignant renal lesions.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
